Reed Masakayan

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Eric L. Smith, Kim Harrington, Reed Masakayan et al. · Science Translational Medicine · 2019 · 385 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

Eric L. Smith, Reed Masakayan, Ishan J. Tatake et al. · Molecular Therapy · 2018 · 125 citations · Full text

Medicine, Immunology, Oncology +17

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

Terese Hammond, Marco A. Purbhoo, Sapana Kadel et al. · Nature Communications · 2024 · 38 citations · Full text

Life Sciences, Immunology, Oncology +17

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Eric L. Smith, Kimberly H. Harrington, Reed Masakayan et al. · Blood · 2018 · 21 citations

Medicine, Immunology, Oncology +16

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Eric L. Smith, Sham Mailankody, Arnab Ghosh et al. · Blood · 2017 · 17 citations

Life Sciences, Immunology, Oncology +16